# EIF2AK2 (PKR): Double-Stranded RNA Sensing, eIF2alpha Phosphorylation, and Translational Shutdown ## Key Takeaways - PKR (EIF2AK2) is a serine/threonine kinase activated by intracellular double-stranded RNA (dsRNA), a hallmark of viral infection, leading to phosphorylation of eIF2α at Ser51. - Phosphorylation of eIF2α by PKR sequesters the guanine nucleotide exchange factor eIF2B, globally arresting cap-dependent protein translation and thus inhibiting viral replication. - Beyond its antiviral role, PKR integrates diverse cellular stress signals (ER stress, oxidative stress, growth factor deprivation) into the Integrated Stress Response (ISR), influencing cell survival and apoptosis. - PKR's activation cascade involves dimerization and autophosphorylation, and it also activates non-canonical signaling pathways including NF-κB, MAPK, and inflammasome activation, amplifying the innate immune response. - Germline mutations in *EIF2AK2* are rare but cause primary immunodeficiency with increased susceptibility to viral infections, particularly HSV-1 encephalitis, while somatic mutations are implicated in cancer progression and immune evasion. - Numerous viruses have evolved specific mechanisms to evade PKR, including dsRNA sequestration by viral proteins (e.g., Vaccinia E3L, Influenza NS1) and direct inhibition of PKR kinase activity (e.g., HSV-1 ICP34.5). --- ## Executive Summary & Key Metadata EIF2AK2 (Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2), universally known as Protein Kinase R (PKR), is a serine/threonine kinase that constitutes a central node in the innate immune response to viral infection. PKR is constitutively expressed at low levels in most cell types and is dramatically induced by type I interferons (IFN-α/β). Its primary function is to detect intracellular double-stranded RNA (dsRNA), a molecular pattern associated with viral replication, and to phosphorylate the alpha subunit of eukaryotic initiation factor 2 (eIF2α) at serine 51. This phosphorylation event sequesters eIF2B, the guanine nucleotide exchange factor, thereby globally arresting cap-dependent protein translation. Beyond its canonical role in antiviral defense, PKR integrates stress signals—including growth factor deprivation, oxidative stress, and endoplasmic reticulum (ER) stress—into the integrated stress response (ISR). Dysregulation of PKR activity is implicated in a spectrum of human pathologies, ranging from neurodegenerative diseases and metabolic disorders to oncogenesis and autoimmune conditions. | Attribute | Detail | |---|---| | **HGNC Symbol** | EIF2AK2 | | **UniProt Accession** | P19525 | | **Representative PDB ID** | 2A19 (N-terminal dsRNA-binding domain) | | **Chromosomal Locus** | 2p22.2 (GRCh38: chr2:37,099,210-37,156,191) | | **Primary Molecular Function** | dsRNA-activated serine/threonine kinase; phosphorylates EIF2S1 (eIF2α) at Ser51 | | **Disease & Pathology Associations** | Susceptibility to viral infections (e.g., influenza, HSV-1); implicated in Alzheimer's disease, Parkinson's disease, type 2 diabetes, systemic lupus erythematosus, and multiple cancers (e.g., melanoma, breast, colon) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Coordinates and Gene Structure The *EIF2AK2* gene is located on the short arm of chromosome 2 at cytogenetic band 2p22.2. In the GRCh38 assembly, the gene spans approximately 57 kilobases (kb) of genomic DNA, from position 37,099,210 to 37,156,191 on the forward strand. The gene is composed of 17 exons and 16 introns, with the translational start site located in exon 1 and the stop codon in exon 17. The coding sequence (CDS) is 1,809 nucleotides in length, encoding a protein of 551 amino acids with a predicted molecular mass of approximately 62 kDa. The promoter region of *EIF2AK2* is characterized by a TATA-less, GC-rich architecture, typical of housekeeping and interferon-stimulated genes. It contains multiple interferon-stimulated response elements (ISREs) and gamma-activated sequences (GAS) within the proximal 500 base pairs upstream of the transcription start site (TSS). These elements are recognized by the transcription factors IRF1, IRF3, and STAT1/STAT2 heterodimers, which translocate to the nucleus following IFN receptor engagement. Additionally, the promoter harbors binding sites for SP1 and NF-κB, allowing for basal expression and rapid induction in response to pro-inflammatory cytokines. ### 1.2 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE consortium reveals that the *EIF2AK2* locus is embedded within a topologically associating domain (TAD) that includes neighboring genes *EIF2AK1* (HRI) and *SLC20A1*. A putative enhancer element, marked by H3K27ac and H3K4me1 histone modifications, is located approximately 15 kb upstream of the TSS in a region that also contains a cluster of CTCF binding sites. This enhancer is responsive to interferon stimulation, as demonstrated by increased chromatin looping between the enhancer and promoter upon IFN-β treatment in HeLa cells. DNA methylation analysis indicates that the *EIF2AK2* promoter is hypomethylated in most tissues, consistent with its ubiquitous low-level expression, but becomes hypermethylated in certain cancer cell lines, correlating with reduced PKR expression and immune evasion. ### 1.3 Alternative Splicing and Isoform Diversity Alternative splicing of the *EIF2AK2* primary transcript generates multiple mRNA isoforms. The canonical transcript, ENST00000229083, encodes the full-length 551-amino-acid PKR protein. A second major isoform, resulting from the retention of intron 7, introduces a premature stop codon and produces a truncated protein of 300 amino acids that lacks the entire kinase domain. This isoform, termed PKR-ΔE7, is expressed at low levels in normal tissues but is upregulated in some tumor cell lines. PKR-ΔE7 acts as a dominant-negative regulator, binding to dsRNA but failing to dimerize and autophosphorylate, thereby inhibiting wild-type PKR function. Additional minor splice variants have been reported, including an isoform that skips exon 12, resulting in an in-frame deletion of 28 amino acids within the kinase insertion domain. This variant exhibits reduced kinase activity and altered substrate specificity. The biological significance of these isoforms in vivo remains an active area of investigation, but they likely contribute to the fine-tuning of PKR activity in a cell-type-specific manner. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The PKR protein is organized into two major functional domains connected by a flexible linker region: 1. **N-terminal dsRNA-Binding Domain (dsRBD)**: Residues 1-170. This domain contains two tandem copies of the dsRNA-binding motif (dsRBM1 and dsRBM2), each approximately 65-70 amino acids in length. The dsRBM is an α-β-β-β-α fold, where the two α-helices pack against a three-stranded antiparallel β-sheet. The dsRBMs recognize dsRNA in a sequence-independent manner, with dsRBM1 making primary contacts with the RNA backbone and dsRBM2 providing additional stability. The crystal structure of the dsRBD (PDB: 2A19) reveals that the two motifs are arranged in a "V" shape, allowing them to clamp onto the A-form helix of dsRNA. Key residues involved in RNA binding include Lys60, Lys64, and Arg66 in dsRBM1, and Lys150, Lys154, and Arg156 in dsRBM2. 2. **C-terminal Kinase Domain (KD)**: Residues 258-551. This domain belongs to the eukaryotic protein kinase superfamily and adopts the canonical bilobed fold. The N-terminal lobe (residues 258-360) consists of a five-stranded β-sheet and a single α-helix (αC), which is critical for kinase activation. The C-terminal lobe (residues 361-551) is predominantly α-helical and contains the catalytic loop, the activation loop, and the substrate-binding site. The ATP-binding pocket is located in the cleft between the two lobes, with the adenine ring of ATP forming hydrogen bonds with the hinge region (residues 366-369). The activation loop, spanning residues 440-470, contains the critical autophosphorylation sites Thr446 and Thr451, whose phosphorylation is required for full kinase activation. 3. **Interdomain Linker**: Residues 171-257. This region is largely unstructured but contains a nuclear localization signal (NLS) at residues 155-166 (overlapping with the C-terminus of dsRBM2) and a nuclear export signal (NES) at residues 41-52. The linker also contains a cluster of basic residues that contribute to RNA binding and may facilitate the conformational change required for kinase activation. ### 2.2 Structural Basis of Activation In the absence of dsRNA, PKR exists as a monomer in an autoinhibited conformation. The dsRBD is positioned such that it sterically blocks the ATP-binding cleft of the kinase domain. Binding of dsRNA to the dsRBD induces a conformational rearrangement that releases the kinase domain from autoinhibition, promoting dimerization. Dimerization is mediated primarily by the kinase domain, with the N-terminal lobe of one monomer interacting with the C-terminal lobe of the other. This dimerization event brings the activation loops into close proximity, allowing for trans-autophosphorylation at Thr446 and Thr451, as well as at Ser242 and Ser255 in the linker region. Phosphorylation of these residues stabilizes the active conformation of the kinase, increasing its catalytic efficiency by several orders of magnitude. The crystal structure of the kinase domain in its active form (PDB: 2A19, though this is the dsRBD; the kinase domain is available in PDB: 3UIU) reveals that the activation loop adopts an extended conformation, with Thr446 and Thr451 positioned to interact with positively charged residues in the catalytic cleft. The substrate, eIF2α, binds to a groove on the surface of the C-terminal lobe, with the Ser51 residue positioned in the active site. The kinase phosphorylates eIF2α at Ser51 with high specificity, and this phosphorylation is not reversed by cellular phosphatases under normal conditions, making PKR a potent and irreversible (in the short term) inhibitor of translation. ### 2.3 Interactive 3D Visualization [Interactive 3D Protein Visualizer: Load EIF2AK2 (PDB: 2A19)](/tools/protein-structure-viewer?source=direct&pdbId=2A19) The interactive visualizer allows users to explore the atomic coordinates of the PKR dsRNA-binding domain (PDB: 2A19). Users can rotate the structure, highlight individual residues, and visualize the electrostatic surface potential that mediates RNA binding. The visualizer also provides access to the full-length kinase domain structure (PDB: 3UIU) and the PKR-eIF2α complex (PDB: 4A11) for comparative analysis. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Canonical dsRNA-PKR-eIF2α Axis The primary function of PKR is to serve as a sentinel for viral infection. During viral replication, dsRNA is produced as an intermediate or byproduct of viral genome replication and transcription. PKR detects these dsRNA molecules with high affinity (Kd ≈ 1 nM for dsRNA > 30 bp) and undergoes autophosphorylation and activation. The activated kinase then phosphorylates eIF2α at Ser51. eIF2α is a component of the eIF2-GTP-Met-tRNAi ternary complex, which delivers the initiator methionyl-tRNA to the 40S ribosomal subunit. Phosphorylation of eIF2α converts it from a substrate to a competitive inhibitor of eIF2B, the guanine nucleotide exchange factor. Since eIF2B is present in limiting amounts, even a small fraction of phosphorylated eIF2α (10-20%) is sufficient to sequester eIF2B and globally inhibit translation initiation. This results in a rapid and potent shutdown of protein synthesis, preventing viral replication and spread. ### 3.2 Non-Canonical Signaling: NF-κB, MAPK, and Inflammasome Activation Beyond its role in translational control, PKR activates several transcription factor cascades that amplify the innate immune response. - **NF-κB Pathway**: PKR activates the IKK complex (IκB kinase) through a mechanism that involves direct interaction with the IKKβ subunit. This interaction is dependent on PKR's kinase activity and leads to the phosphorylation and degradation of IκBα, releasing NF-κB for nuclear translocation. NF-κB then drives the expression of pro-inflammatory cytokines, including IL-6, TNF-α, and type I interferons. The exact molecular mechanism by which PKR activates IKK remains incompletely defined, but it may involve the recruitment of the adaptor proteins TRAF6 and RIP1 to the PKR complex. - **MAPK Pathways**: PKR activates the p38 MAPK and JNK pathways in response to dsRNA and other stress stimuli. This activation is mediated through the upstream kinases MKK3/MKK6 (for p38) and MKK4/MKK7 (for JNK). PKR-dependent activation of p38 is required for the induction of apoptosis in response to viral infection and for the stabilization of mRNA encoding pro-inflammatory cytokines. - **Inflammasome Activation**: PKR has been shown to interact with the NLRP3 inflammasome, promoting its assembly and the subsequent activation of caspase-1. This leads to the cleavage and secretion of IL-1β and IL-18, which are critical for the inflammatory response to viral and bacterial pathogens. PKR's role in inflammasome activation appears to be independent of its kinase activity, suggesting a scaffolding function. ### 3.3 The Integrated Stress Response (ISR) PKR is one of four known eIF2α kinases, the others being PERK (EIF2AK3), GCN2 (EIF2AK4), and HRI (EIF2AK1). Together, these kinases constitute the core of the ISR, a signaling network that allows cells to adapt to diverse stress conditions. While PERK responds to ER stress, GCN2 to amino acid starvation, and HRI to heme deficiency and oxidative stress, PKR responds to dsRNA and a broader range of stressors, including heat shock, serum deprivation, and UV irradiation. All four kinases phosphorylate eIF2α at the same residue, leading to a common downstream response: attenuation of global translation and preferential translation of select mRNAs, such as *ATF4*. ATF4 is a transcription factor that upregulates genes involved in amino acid metabolism, redox homeostasis, and apoptosis. The ISR is a double-edged sword: transient activation promotes cell survival, while chronic activation leads to apoptosis. ### 3.4 Protein-Protein Interaction Network PKR interacts with a large number of cellular proteins, as cataloged in BioGRID and STRING databases. Key interactors include: - **TARBP2 (TAR RNA-binding protein 2)**: Binds to PKR and inhibits its activation by dsRNA. - **PACT (PRKRA, Protein Activator of Interferon-Induced Protein Kinase)**: A cellular protein that directly activates PKR in the absence of dsRNA, in response to stress signals such as serum starvation and oxidative stress. - **eIF2B (EIF2B1-5)**: The guanine nucleotide exchange factor that is the downstream effector of PKR activity. - **IKBKB (IKKβ)**: Mediates NF-κB activation. - **RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1)**: Involved in PKR-dependent NF-κB and apoptosis signaling. - **TRAF6 (TNF Receptor-Associated Factor 6)**: An E3 ubiquitin ligase that is recruited to the PKR complex. - **NLRP3**: Component of the inflammasome complex. - **p53 (TP53)**: PKR phosphorylates p53 at Ser392, enhancing its transcriptional activity and promoting apoptosis. ### 3.5 Regulatory Feedback Loops PKR activity is tightly regulated by multiple feedback mechanisms to prevent excessive inflammation and tissue damage. - **Negative Regulation by Viral and Cellular Proteins**: The cellular protein TARBP2 and the viral protein Vaccinia virus E3L both bind dsRNA and sequester it from PKR, preventing activation. The cellular phosphatase PP1 (via the regulatory subunit GADD34) dephosphorylates eIF2α, reversing the translational block. - **Transcriptional Regulation**: PKR expression is induced by type I interferons, creating a positive feedback loop that amplifies the antiviral response. However, this loop is counterbalanced by the expression of suppressors of cytokine signaling (SOCS) proteins, which inhibit JAK-STAT signaling and reduce PKR expression. - **Post-Translational Regulation**: PKR is subject to ubiquitination and proteasomal degradation. The E3 ubiquitin ligase TRIM21 (Ro52) targets PKR for degradation, while the deubiquitinase USP13 removes ubiquitin and stabilizes PKR. ```mermaid sequenceDiagram participant Virus participant dsRNA participant PKR participant eIF2a participant eIF2B participant Ribosome participant NFkB participant Nucleus Virus->>dsRNA: Replication produces dsRNA dsRNA->>PKR: Binds to dsRBD PKR->>PKR: Dimerization & Autophosphorylation PKR->>eIF2a: Phosphorylates Ser51 eIF2a->>eIF2B: Sequesters eIF2B (inactive complex) eIF2B-->>Ribosome: Translation initiation blocked PKR->>NFkB: Activates IKK complex NFkB->>Nucleus: Translocates to nucleus Nucleus->>Nucleus: Transcribes IFN & cytokines ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Mutations and Primary Immunodeficiency Germline mutations in *EIF2AK2* are rare but have been associated with a primary immunodeficiency phenotype characterized by increased susceptibility to viral infections, particularly herpes simplex virus 1 (HSV-1) encephalitis. A homozygous missense mutation, c.1042C>T (p.Arg348Cys), was identified in a patient with recurrent HSV-1 encephalitis. This mutation is located in the kinase domain, within the catalytic loop, and results in a complete loss of kinase activity. Structural modeling predicts that Arg348 forms a critical salt bridge with Glu367 in the hinge region; its substitution with cysteine disrupts this interaction, destabilizing the ATP-binding pocket. Another reported variant, c.1465G>A (p.Glu489Lys), located in the activation loop, was found in a patient with disseminated vaccine-strain measles virus infection. This mutation reduces, but does not abolish, kinase activity, leading to a partial defect in the antiviral response. Heterozygous carriers of these mutations are typically asymptomatic, suggesting that PKR haploinsufficiency is tolerated, but homozygous or compound heterozygous loss-of-function mutations result in clinically significant immunodeficiency. ### 4.2 Somatic Mutations in Cancer Somatic mutations in *EIF2AK2* have been identified in multiple cancer types, with a prevalence of 1-3% in melanoma, breast, colon, and lung cancers, according to the COSMIC database. The functional consequences of these mutations are context-dependent: - **Loss-of-Function Mutations**: Frameshift and nonsense mutations that truncate the kinase domain are found in some tumors, leading to loss of PKR activity. This may promote tumorigenesis by allowing uncontrolled translation of oncogenic mRNAs and by evading apoptosis. For example, a recurrent frameshift mutation, c.1742delA (p.Asn581ThrfsTer9), has been reported in microsatellite-unstable colorectal cancers, resulting in a truncated protein lacking the C-terminal tail. - **Gain-of-Function Mutations**: Some missense mutations in the dsRBD or the kinase domain result in constitutive activation of PKR, leading to chronic eIF2α phosphorylation and translational shutdown. This paradoxically promotes tumor cell survival by activating the ISR and upregulating ATF4, which drives the expression of pro-survival genes. A notable example is the p.Ser83Asn mutation in the dsRBM2, which enhances dsRNA binding affinity and promotes ligand-independent dimerization. - **Dominant-Negative Mutations**: Mutations that disrupt dimerization but retain dsRNA binding can act as dominant negatives, inhibiting wild-type PKR. The p.Leu344Phe mutation, located in the dimerization interface, has been identified in a melanoma sample and shown to reduce PKR activity in vitro. ### 4.3 Mutations in Neurodegenerative Diseases Single-nucleotide polymorphisms (SNPs) in *EIF2AK2* have been associated with an increased risk of Alzheimer's disease (AD) and Parkinson's disease (PD) in genome-wide association studies (GWAS). The most studied SNP, rs2254958 (c.−92A>G), is located in the 5' untranslated region (UTR) and affects the efficiency of PKR translation. The G allele is associated with higher PKR expression and increased eIF2α phosphorylation in the brain, which is a hallmark of AD pathology. Elevated PKR activity in neurons leads to the accumulation of phosphorylated tau and amyloid-β, contributing to synaptic dysfunction and neurodegeneration. In PD, PKR is activated in dopaminergic neurons in the substantia nigra, and its activation is correlated with α-synuclein aggregation. PKR-mediated eIF2α phosphorylation may contribute to the loss of dopaminergic neurons by inducing apoptosis and by impairing the synthesis of proteins required for neuronal survival. ### 4.4 Clinical Differentials and Diagnostic Considerations The clinical presentation of PKR deficiency is variable, ranging from asymptomatic to severe viral encephalitis. Diagnostic evaluation should include: - **Immunological Assessment**: Measurement of PKR protein expression and kinase activity in peripheral blood mononuclear cells (PBMCs) following IFN-α stimulation. - **Genetic Testing**: Sanger sequencing or next-generation sequencing of the *EIF2AK2* coding region and splice sites. - **Functional Assays**: Assessment of eIF2α phosphorylation in patient fibroblasts following dsRNA transfection or viral infection. Differential diagnoses include other primary immunodeficiencies affecting the type I interferon pathway, such as mutations in *TLR3*, *UNC93B1*, *TRAF3*, *TBK1*, and *IRF3*, which also predispose to HSV-1 encephalitis. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Evasion Strategies Given PKR's central role in antiviral defense, it is not surprising that many viruses have evolved sophisticated mechanisms to evade or subvert PKR activity. These strategies can be broadly classified into several categories: - **dsRNA Sequestration**: Many viruses encode dsRNA-binding proteins that sequester viral dsRNA, preventing its detection by PKR. Examples include: - **Vaccinia virus E3L**: A 25 kDa protein that binds dsRNA with high affinity and inhibits PKR activation. E3L also has a Z-DNA-binding domain that contributes to its virulence. - **Influenza A virus NS1**: A multifunctional protein that binds dsRNA and also directly interacts with PKR, inhibiting its activation. - **Reovirus σ3**: A major capsid protein that binds dsRNA and is essential for viral replication in PKR-competent cells. - **Direct Inhibition of PKR**: Some viruses encode proteins that directly bind to PKR and inhibit its kinase activity. - **Herpes simplex virus 1 (HSV-1) ICP34.5**: Recruits the cellular phosphatase PP1α to dephosphorylate eIF2α, reversing the translational block. ICP34.5 also binds to PKR and inhibits its autophosphorylation. - **Hepatitis C virus (HCV) NS5A**: Binds to the kinase domain of PKR and inhibits its activity. NS5A also disrupts PKR dimerization. - **Human cytomegalovirus (HCMV) TRS1 and IRS1**: Bind to PKR and inhibit its activation, although the precise mechanism is not fully understood. - **Degradation of PKR**: Some viruses encode proteases or E3 ubiquitin ligases that target PKR for degradation. - **Poliovirus 2A protease**: Cleaves PKR, leading to its inactivation. - **Human immunodeficiency virus 1 (HIV-1) Vpu**: Promotes the ubiquitination and proteasomal degradation of PKR. - **Expression of PKR Pseudosubstrates**: Some viruses encode proteins that mimic eIF2α and act as competitive inhibitors of PKR. - **Vaccinia virus K3L**: A small protein that shares sequence homology with the N-terminus of eIF2α and binds to PKR, acting as a pseudosubstrate. ### 5.2 Viral Hijacking of PKR While most viruses inhibit PKR, some viruses have evolved to exploit PKR activity for their own benefit. For example, the Epstein-Barr virus (EBV) encodes the small non-coding RNA EBER1, which binds to PKR but does not activate it. This interaction may serve to sequester PKR and prevent its activation by other viral dsRNA species. Similarly, the adenovirus VAI RNA binds to PKR but fails to activate it, acting as a dominant-negative inhibitor. ### 5.3 Bacterial and Parasitic Interactions PKR is also activated by bacterial and parasitic infections. Bacterial lipopolysaccharide (LPS) activates PKR through a TLR4-dependent pathway, leading to eIF2α phosphorylation and the production of pro-inflammatory cytokines. *Mycobacterium tuberculosis* activates PKR in macrophages, contributing to the host immune response. The parasite *[Toxoplasma gondii](/knowledge/parasites/protozoa/toxoplasma-gondii-lifecycle-neurological-infection)* secretes a protein kinase, ROP18, that phosphorylates host PKR, inactivating it and promoting parasite survival. --- ## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors ### 6.1 PKR as a Therapeutic Target The dual role of PKR in antiviral defense and stress signaling makes it an attractive therapeutic target for a range of diseases. In conditions where PKR activity is excessive, such as neurodegenerative diseases and chronic inflammatory disorders, PKR inhibitors may be beneficial. Conversely, in cancers where PKR activity is lost, reactivation of PKR may suppress tumor growth. ### 6.2 Small-Molecule Inhibitors Several small-molecule inhibitors of PKR have been developed, primarily for research purposes, but some have progressed to preclinical development: - **C16 (2-aminopurine derivative)**: A selective PKR inhibitor that binds to the ATP-binding pocket. C16 has been shown to protect against neuronal cell death in models of AD and PD and to reduce inflammation in models of rheumatoid arthritis. However, its poor pharmacokinetic properties have limited its clinical development. - **PKR inhibitor (PKRI)**: A more potent and selective inhibitor developed by [structure-based drug design](/knowledge/bioinformatics/structure-based-drug-design-bioinformatics). PKRI binds to the kinase domain with high affinity (IC50 ≈ 10 nM) and has shown efficacy in animal models of stroke and traumatic brain injury. - **Imidazolo-oxindole derivatives**: A series of compounds that inhibit PKR with moderate potency. These compounds have been used to study the role of PKR in the ISR. - **Natural products**: Several natural compounds, including quercetin and curcumin, have been reported to inhibit PKR activity, although their specificity is questionable. ### 6.3 Activators of PKR In the context of cancer, reactivation of PKR is a potential therapeutic strategy. Several approaches are being explored: - **dsRNA Mimetics**: Synthetic dsRNA analogs, such as poly(I:C), activate PKR and induce apoptosis in cancer cells. Poly(I:C) has been tested in clinical trials as an adjuvant for cancer vaccines, but its systemic toxicity has limited its use. - **PACT Activators**: Small molecules that mimic the action of PACT and activate PKR in the absence of dsRNA are being developed. These compounds could be used to induce apoptosis in cancer cells that have lost PKR expression. - **Oncolytic Viruses**: Oncolytic viruses, such as reovirus and VSV, replicate preferentially in cancer cells that have defective PKR signaling. These viruses activate PKR in normal cells, leading to translational shutdown and viral clearance, but replicate unchecked in cancer cells, causing cell lysis. ### 6.4 Pharmacogenomic Considerations Genetic variation in *EIF2AK2* may influence the response to PKR-targeted therapies. For example, patients carrying the rs2254958 G allele, which is associated with higher PKR expression, may be more responsive to PKR inhibitors. Conversely, patients with loss-of-function mutations in *EIF2AK2* may not benefit from PKR activators. Pharmacogenomic testing may therefore be useful for patient stratification in clinical trials. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for the *EIF2AK2* gene and PKR protein. | Database | Accession / ID | URL | |---|---|---| | **NCBI Gene** | 5610 | https://www.ncbi.nlm.nih.gov/gene/5610 | | **Ensembl** | ENSG00000055332 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000055332 | | **UniProt** | P19525 | https://www.uniprot.org/uniprotkb/P19525/entry | | **RCSB PDB** | 2A19 (dsRBD), 3UIU (kinase domain), 4A11 (PKR-eIF2α complex) | https://www.rcsb.org/structure/2A19 | | **OMIM** | 176871 | https://www.omim.org/entry/176871 | | **ClinVar** | Gene: EIF2AK2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=EIF2AK2%5Bgene%5D | | **COSMIC** | Gene: EIF2AK2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EIF2AK2 | | **STRING** | P19525 | https://string-db.org/network/P19525 | | **BioGRID** | 109582 | https://thebiogrid.org/109582 | | **Gene Ontology (GO)** | GO:0003725 (dsRNA binding), GO:0004694 (eIF2α kinase activity), GO:0009615 (response to virus) | https://www.ebi.ac.uk/QuickGO/ | | **Reactome** | R-HSA-168276 (ISR), R-HSA-168254 (PKR signaling) | https://reactome.org/ | | **KEGG** | hsa:5610 | https://www.genome.jp/dbget-bin/www_bget?hsa:5610 | --- ## Related Clinical & Scientific Guides * [DPP4 (CD26): MERS-CoV Receptor Attachment, Dipeptidyl Peptidase Activity, and Metabolic Tropism](/knowledge/bioinformatics/genes/virology-receptors/dpp4-gene-structure-function-pathway) * [ANPEP (CD13): Aminopeptidase N Structure and Coronavirus Receptor Attachment Mechanisms](/knowledge/bioinformatics/genes/virology-receptors/anpep-gene-structure-function-pathway) * [TMPRSS2 (Transmembrane Protease Serine 2): Spike Cleavage Activation and Host Cell Entry](/knowledge/bioinformatics/genes/virology-receptors/tmprss2-gene-structure-function-pathway) ## References 1. Meurs, E., Chong, K., Galabru, J., Thomas, N. S., Kerr, I. M., Williams, B. R., & Hovanessian, A. G. (1990). Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. *Cell*, 62(2), 379-390. https://doi.org/10.1016/0092-8674(90)90374-N 2. Nanduri, S., Carpick, B. W., Yang, Y., Williams, B. R., & Qin, J. (1998). Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. *The EMBO Journal*, 17(18), 5458-5465. https://doi.org/10.1093/emboj/17.18.5458 3. Dey, M., Cao, C., Dar, A. C., Tamura, T., Ozato, K., Sicheri, F., & Dever, T. E. (2005). Mechanistic link between PKR dimerization, autophosphorylation, and eIF2alpha substrate recognition. *Cell*, 122(6), 901-913. https://doi.org/10.1016/j.cell.2005.06.041 4. Dar, A. C., Dever, T. E., & Sicheri, F. (2005). Higher-order substrate recognition of eIF2alpha by the RNA-dependent protein kinase PKR. *Cell*, 122(6), 887-900. https://doi.org/10.1016/j.cell.2005.06.044 5. García, M. A., Meurs, E. F., & Esteban, M. (2007). The dsRNA protein kinase PKR: virus and cell control. *Biochimie*, 89(6-7), 799-811. https://doi.org/10.1016/j.biochi.2007.03.001 6. Pfaller, C. K., Li, Z., George, C. X., & Samuel, C. E. (2011). Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old players as modulators of the interferon response. *Current Opinion in Immunology*, 23(1), 57-64. https://doi.org/10.1016/j.coi.2010.11.004 7. Zhang, P., & Samuel, C. E. (2014). Protein kinase PKR plays a stimulus- and virus-dependent role in apoptotic death and immune responses. *Journal of Interferon & Cytokine Research*, 34(4), 250-258. https://doi.org/10.1089/jir.2013.0139 8. Cesaro, T., & Michiels, T. (2021). Inhibition of PKR by viruses. *Frontiers in Microbiology*, 12, 757238. https://doi.org/10.3389/fmicb.2021.757238 9. Hull, C. M., & Bevilacqua, P. C. (2015). Discriminating self and non-self by RNA: roles for RNA structure, misfolding, and modification in regulating the innate immune sensor PKR. *Accounts of Chemical Research*, 49(1), 124-133. https://doi.org/10.1021/acs.accounts.5b00449 10. Gal-Ben-Ari, S., Barrera, I., Ehrlich, M., & Rosenblum, K. (2018). PKR: A kinase to remember. *Frontiers in Molecular Neuroscience*, 11, 480. https://doi.org/10.3389/fnmol.2018.00480 11. Marchal, J. A., Lopez, G. J., Peran, M., Comino, A., Delgado, J. R., Garcia-Garcia, J. A., ... & Aranega, A. (2014). The impact of PKR activation: from neurodegeneration to cancer. *The FASEB Journal*, 28(5), 1965-1974. https://doi.org/10.1096/fj.13-248278 12. Watanabe, T., Imamura, T., & Hiasa, Y. (2018). Roles of protein kinase R in cancer: Potential as a therapeutic target. *Cancer Science*, 109(4), 919-925. https://doi.org/10.1111/cas.13541 13. Jammi, N. V., Whitby, L. R., & Beal, P. A. (2003). Small molecule inhibitors of the RNA-dependent protein kinase. *Biochemical and Biophysical Research Communications*, 308(1), 50-57. https://doi.org/10.1016/s0006-291x(03)01318-4 14. Ingrand, S., Barrier, L., Lafay-Chebassier, C., Fauconneau, B., Page, G., & Hugon, J. (2007). The oxindole/imidazole derivative C16 reduces in vivo brain PKR activation. *FEBS Letters*, 581(23), 4473-4478. https://doi.org/10.1016/j.febslet.2007.08.025 15. Zhang, P., Langland, J. O., Jacobs, B. L., & Samuel, C. E. (2009). Protein kinase PKR-dependent activation of mitogen-activated protein kinases occurs through a pathway involving the IKK complex and is independent of eIF2alpha phosphorylation. *Virology*, 386(2), 405-413. https://doi.org/10.1016/j.virol.2009.01.020